Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 9/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415071 | 1.00 | MAPT (0.35) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL6416370 | 0.83 | MAPT (0.41) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL6416374 | 0.83 | MAPT (0.41) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL13310235 | 0.79 | MAPT (0.46) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL8266101 | 0.78 | KMT2A (0.44) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL6436752 | 0.78 | KMT2A (0.44) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL6415083 | 0.77 | MEN1 (0.47) | MAPTTP53SMN1; SMN2POLBMEN1 | |
| SCHEMBL6432678 | 0.77 | MEN1 (0.51) | MAPTSMN1; SMN2POLBMEN1NPC1 | |
| SCHEMBL3050490 | 0.75 | TP53 (0.53) | MAPTTP53SMN1; SMN2POLBEGFR | |
| SCHEMBL6415073 | 0.75 | EGFR (0.33) | MAPTTP53SMN1; SMN2POLBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | MAPT 4420/4885TP53 4485/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.